Associate Professor
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States
Dr. Arash Naghavi is an Associate Member with Tenure in the Department of Radiation Oncology at Moffitt Cancer Center and an Associate Professor in the Department of Oncologic Sciences at the University of South Florida. He is the Section Chief for the Sarcoma Radiotherapy Service at Moffitt Cancer Center. He is also the Program Director for the Brachytherapy Fellowship and Chair of Program Evaluation Committee for the Radiation Oncology Residency.
After completing a Master of Science in Genetics, Medical Degree from the University of Texas Medical Branch, and Radiation Oncology Residency and a Personalized Medicine Fellowship at Moffitt Cancer Center, he joined as faculty in 2017. He has served on multiple editorial boards, was Editor in Chief for American Brachytherapy spoton, and contributed to the sarcoma consensus guidelines for the American Brachytherapy Society.
Dr. Naghavi’s primary research interest is in the integration of genomics and radiomics to personalize the treatment of soft tissue sarcoma with the goal of expanding our knowledge in radiation sensitivity, immunogenicity, and identifying predictors and potential targets, to optimize patient outcomes. This has led to over 70 peer-reviewed manuscripts, including: sarcoma radiosensitivity or “Genomic Adjusted Radiation Dose (GARD)”, the relationships between pathologic response and outcome, and novel techniques (e.g. Hypofractionated Accelerated Radiation Dose-painting, or “HARD”) to improve outcomes for retroperitoneal sarcoma and unresected sarcoma.
This work has been presented nationally and internationally, culminating in his ongoing phase II Habitat Escalated Adaptive Therapy (HEAT) trial (NCT05301283), utilizing MRI radiomic habitats to identify and target radioresistant intra-tumoral subpopulations with GARD estimated radiation dose escalation, to improve pathologic response and patient outcome. This serves as the first personalized radiotherapy trial for sarcoma, has promising preliminary results, and will help reveal the relationship between genomics, radiomics, and ctDNA to better understand this vastly heterogenous disease.
Disclosure information not submitted.
Friday, November 15, 2024
11:15 AM – 12:45 PM PST
